86 related articles for article (PubMed ID: 26451770)
1. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
2. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
3. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
[TBL] [Abstract][Full Text] [Related]
4. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors.
Lowder MA; Doerner AE; Schepartz A
J Am Chem Soc; 2015 May; 137(20):6456-9. PubMed ID: 25973741
[TBL] [Abstract][Full Text] [Related]
5. Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations.
Yan F; Liu X; Zhang S; Su J; Zhang Q; Chen J
RSC Adv; 2018 Nov; 8(70):39797-39810. PubMed ID: 35558225
[TBL] [Abstract][Full Text] [Related]
6. Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance.
Li Q; Li B; Wang Q; Wang C; Yu M; Xu T
Front Pharmacol; 2024; 15():1396605. PubMed ID: 38751788
[TBL] [Abstract][Full Text] [Related]
7. Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
Heald R; Bowman KK; Bryan MC; Burdick D; Chan B; Chan E; Chen Y; Clausen S; Dominguez-Fernandez B; Eigenbrot C; Elliott R; Hanan EJ; Jackson P; Knight J; La H; Lainchbury M; Malek S; Mann S; Merchant M; Mortara K; Purkey H; Schaefer G; Schmidt S; Seward E; Sideris S; Shao L; Wang S; Yeap K; Yen I; Yu C; Heffron TP
J Med Chem; 2015 Nov; 58(22):8877-95. PubMed ID: 26455919
[TBL] [Abstract][Full Text] [Related]
8. LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Wu Y; Yu DD; Hu Y; Cao HX; Yu SR; Liu SW; Feng JF
Biochem Biophys Res Commun; 2015 Nov; 467(4):900-5. PubMed ID: 26471306
[TBL] [Abstract][Full Text] [Related]
9. Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo.
Han X; Zhang X; Li H; Huang S; Zhang S; Wang F; Shi Y
Oncotarget; 2015 Nov; 6(36):38912-25. PubMed ID: 26498681
[TBL] [Abstract][Full Text] [Related]
10. Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.
Li X; Yang H; Zhao J; Gao H
Onco Targets Ther; 2015; 8():2739-43. PubMed ID: 26491347
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Cui F; Wang W; Wu D; He X; Wu J; Wang M
Clin Transl Oncol; 2016 Jul; 18(7):722-7. PubMed ID: 26474873
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitors that evade paradoxical MAPK pathway activation.
Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
17. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
18. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G; Tseng LH; Chen G; Haley L; Illei P; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2015 Oct; 15():779. PubMed ID: 26498038
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
Sriraman SK; Geraldo V; Luther E; Degterev A; Torchilin V
J Control Release; 2015 Dec; 220(Pt A):160-168. PubMed ID: 26497930
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
